{"id":262807,"date":"2025-01-31T14:29:23","date_gmt":"2025-01-31T13:29:23","guid":{"rendered":"https:\/\/sola-diagnostics.com\/?page_id=262807"},"modified":"2026-06-29T11:13:53","modified_gmt":"2026-06-29T10:13:53","slug":"about","status":"publish","type":"page","link":"https:\/\/sola-diagnostics.com\/en\/about\/","title":{"rendered":"About"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Submen\u00fc” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#7F5E75″ custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” sticky_position=”top” sticky_position_tablet=”none” sticky_position_phone=”none” sticky_position_last_edited=”on|phone” locked=”off” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”10px||10px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”Georgia||||||||” text_text_color=”#FFFCFC” text_font_size=”16px” link_text_color=”#FFFCFC” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

Vision & Mission<\/a> | Value Proposition<\/a> | Leadership Team<\/a> | Milestones<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Herosection” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” width=”100%” module_alignment=”center” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2025\/01\/header_about.png” title_text=”header_about” show_bottom_space=”off” align=”center” force_fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Vision & Mission” module_id=”en_a_vision_mission” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Vision” admin_label=”Heading – Vision” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ title_text_align=”center” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”23px” text_line_height=”1.8em” text_orientation=”center” custom_margin=”||||false|false” locked=”off” global_colors_info=”{}”]<\/p>\n

Our vision is to lead a global transformation in women\u2019s cancer prevention and early diagnosis by making innovative, accessible, and personalized solutions the Standard Of Care\u2014empowering women worldwide to live healthier lives.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Mission” admin_label=”Heading – Vision” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ title_text_align=”center” global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”23px” text_line_height=”1.8em” text_orientation=”center” custom_margin=”||||false|false” locked=”off” global_colors_info=”{}”]<\/p>\n

Our mission is to address unmet needs in women\u2019s cancer prevention and diagnosis by delivering personalized care through innovative epigenetic solutions, driving global access to improve outcomes for women across the globe.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#7F5E75″ divider_position=”center” divider_weight=”2px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Value Proposition” module_id=”en_a_value_proposition” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”on” global_colors_info=”{}”][et_pb_row module_id=”Prinzip” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Value Proposition” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

At Sola Dx, we are revolutionising personalised primary and secondary prevention through ground-breaking innovations, including the WID\u00ae-easy Test for the early detection of endometrial cancer and the WID\u00ae-can Test for cervical cancer risk prediction.<\/p>\n

Our key focus is driving the rapid adoption of the WID\u00ae-easy Test among symptomatic women in major global markets, laying the groundwork for population-wide screening and unlocking substantial market potential.<\/p>\n

The WID\u00ae-can Test is poised to redefine cervical cancer screening as a non-cytology molecular triage tool. Unlike traditional methods reliant on cellular morphology, the WID\u00ae-can Test can be performed on self-collected samples, offering superior objectivity, reproducibility, and accessibility compared to current standards.<\/p>\n

The WID\u00ae-ok Test is designed to identify women at high risk for ovarian cancer, regardless of genetic predisposition. By detecting risk factors beyond hereditary mutations, the WID\u00ae-ok Test enables proactive prevention, offering a crucial opportunity to intervene before this highly lethal disease develops.<\/p>\n

The WID\u00ae-best Test represents a breakthrough in breast cancer risk stratification by leveraging an epigenetic signature detected in cervical smear samples. This cutting-edge test identifies women at heightened risk of developing breast cancer, enabling personalized primary prevention strategies and facilitating risk-adjusted screening protocols.<\/p>\n

Through our unwavering commitment to innovation, we are addressing the critical diagnostic needs of women today while paving the way for a future where personalized, accessible, and effective cancer prevention becomes the global Standard Of Care.<\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”What We Do” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

We develop and market minimally invasive epigenetic diagnostic tools, including the WID\u00ae-easy and WID\u00ae-can Tests, designed to detect gynaecological cancers at an early stage, when treatments are most effective, and success rates are highest. Leveraging the same cervico-vaginal sample, we are pioneering the development of adaptable epigenetic risk markers, such as the WID\u00ae-best Test, with the potential to enable personalized prevention strategies for other women\u2019s cancers as well.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Why We’re Different” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

At Sola Dx, we are a commercial-stage epigenetic diagnostics company built on over 30 years of ground-breaking research in DNA methylation and gynaecological cancers. Our technologies originate from the pioneering work of Prof. Martin Widschwendter<\/a> and his world-renowned academic team. Leveraging cutting-edge epigenetic science, we develop diagnostic tests that are both highly accurate and minimally invasive. By focusing on tailored precision prevention, we empower women with the knowledge and tools to make better informed health decisions, setting us apart as leaders in women\u2019s health diagnostics.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Divider” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” saved_tabs=”all” collapsed=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”0px||0px||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_divider color=”#7F5E75″ divider_position=”center” divider_weight=”2px” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Section – Leadership” module_id=”en_a_leadership” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#FFFCFC” custom_padding=”|20px||20px|false|false” collapsed=”off” global_colors_info=”{}”][et_pb_row admin_label=”Row” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Leadership Team” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h2″ global_colors_info=”{}”][\/et_pb_heading][et_pb_heading title=”Executive Team” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.27.7″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Sara Sleigh, PhD” position=”Chief Development Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Sleigh-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/sara-sleigh-4a95954\/” disabled_on=”off|off|off” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}” title_text=”Sleigh” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Peter Kayatz, PhD” position=”Chief Executive Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Kayatz-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/kayatz\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” title_text=”Kayatz” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”David Tschabitscher, MA” position=”Chief Operating Officer” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Tschabitscher-2.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/david-tschabitscher\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” title_text=”Tschabitscher” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Elisa Redl, PhD” position=”Head of Analytical Development” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Redl-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/elisa-redl-50128b226\/” _builder_version=”4.27.7″ _module_preset=”default” position_text_align=”center” text_orientation=”center” custom_margin=”||||false|false” hover_enabled=”0″ custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}” title_text=”Redl” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Deepali Patel, MSc” position=”Head of Clinical Research” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Patel-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/dee-patel-0865873a7\/” _builder_version=”4.27.7″ _module_preset=”default” position_text_align=”center” text_orientation=”center” custom_margin=”||||false|false” hover_enabled=”0″ custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}” title_text=”Patel” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Sebastian Gr\u00f6mminger, PhD” position=”Regulatory Advisor” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Gromminger-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/sebastian-groemminger\/” _builder_version=”4.27.7″ _module_preset=”default” position_text_align=”center” text_orientation=”center” custom_margin=”||||false|false” hover_enabled=”0″ custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}” title_text=”Gr\u00f6mminger” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Michael Lutz, PhD” position=”Strategic Advisor” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Lutz-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/michael-lutz-90a7513\/” _builder_version=”4.27.7″ _module_preset=”default” position_text_align=”center” text_orientation=”center” custom_margin=”||||false|false” hover_enabled=”0″ custom_css_free_form=”.et_pb_team_member_image {||width: 100%;||display: block;||margin: 0 auto 22px;||}” global_colors_info=”{}” title_text=”Lutz” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row admin_label=”Row” _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Scientific Advisory Board” _builder_version=”4.27.7″ _module_preset=”default” title_level=”h3″ hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.27.4″ _module_preset=”default” module_alignment=”center” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Martin Widschwendter” position=”Advisor for Epigenetic Risk Prediction” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Widschwendter-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/martin-widschwendter-66453b3b\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” title_text=”Widschwendter” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Hon. Prof. Adeola Olaitan” position=”Advisor for Gynaecological Oncology” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Olaitan-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/adeola-olaitan-788a2448\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″ title_text=”Olaitan”][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Nora Pashayan” position=”Advisor for Risk-Stratified Cancer Screening” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Pashayan-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/nora-pashayan-bb980545\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″ title_text=”Pashayan”][\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.27.4″ _module_preset=”default” module_alignment=”center” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Prof. Silvia de Sanjos\u00e9” position=”Advisor for Viral Oncology and Epidemiology” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Sanjose-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/silvia-de-sanjose-92083531\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” title_text=”Sanjose” sticky_enabled=”0″][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”Ass. Prof. Chiara Herzog” position=”Advisor for Epigenetic Biomarker Innovation” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Herzog-2.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/chiara-herzog\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″ title_text=”Herzog”][\/et_pb_team_member][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_team_member name=”James Barrett, PhD” position=”Advisor for Statistics & Bioinformatics” image_url=”https:\/\/sola-diagnostics.com\/wp-content\/uploads\/2026\/06\/Barrett-1.png” linkedin_url=”https:\/\/www.linkedin.com\/in\/james-e-barrett-71064685\/” _builder_version=”4.27.7″ _module_preset=”default” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″ title_text=”Barrett”][\/et_pb_team_member][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Our Impact” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

Our innovative diagnostics are designed to reduce morbidity and mortality from women\u2019s cancers through precision prevention and early detection.<\/p>\n

The WID\u00ae-easy Test minimises the need for unnecessary surgical procedures, lowering healthcare costs, protecting women from invasive interventions, and enhancing the effectiveness of early cancer detection.<\/p>\n

The WID\u00ae-can Test benefits patients by offering an accessible, minimally invasive cervical cancer screening solution that can be performed on self-collected samples, reducing discomfort, increasing accessibility, and delivering more accurate and reproducible results.<\/p>\n

The WID\u00ae-best Test empowers women by identifying their elevated risk of breast cancer through minimally invasive analysis of cervical smear samples, enabling personalized prevention strategies and proactive health management.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_heading title=”Our Values” _builder_version=”4.27.4″ _module_preset=”default” title_level=”h3″ global_colors_info=”{}”][\/et_pb_heading][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n